Healthcare News

Dr. Shahidi beschikt over uitgebreide expertise op het gebied van geneesmiddelenontwikkeling, succesvolle registratieprocedures en baanbrekende operationele ervaring naar de Raad van Bestuur ...

- Keith A. Goldan to retire as CFO and remain with the Company through year-end to support the transition - NEW YORK, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a...

WATERTOWN, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation...

– Total revenue of $83.3 million in 3Q26, an 82% year-over-year increase – – Revuforj® (revumenib) net revenue of $60.7 million in 3Q26, a 90% y/y increase, underscores leadership in R/R NPM1m and...

– CASGEVY® revenue of $99 million in the third quarter of 2026, up 30% quarter-over-quarter and nearly six times the third quarter of 2025 – – CASGEVY approved in the U.K. for children 5 years of age...

NEW YORK and WALTHAM, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to...

SOUTH SAN FRANCISCO, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver...

WAYNE, Pa., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company dedicated to developing therapeutics targeting the IL-1β pathway for...

1 October 2025 - 30 September 2026 Coloplast delivered 5% organic growth in Q4, driven by continued strength in Chronic Care and Interventional Urology. EBIT growth1 in constant currencies was 0% and...

1. oktober 2025 - 30. september 2026 Coloplast leverede 5% organisk vækst i 4. kvartal, drevet af fortsat stærk vækst i Chronic Care og Urologi. EBIT-væksten¹ i faste valutakurser var 0% og...